Study S000199

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Taspoglutide on Glycemic Control, and Its Safety and Tolerability, in Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy.

ClinicalTrials.gov record

Registration

Registration: NCT00823992
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 305
Start: 2009-01
Primary completion: 2010-05
Lead sponsor: Hoffmann-La Roche
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:placebo; DRUG:taspoglutide
Results posted: FALSE
Secondary identifiers: OTHER:2008-005809-20; NIH:2008

Registered primary outcomes

Absolute change from baseline in HbA1c [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.